Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Conditions
Brief summary
Budesonide + Procaterol HFA MDI is a novel asthma product containing both budesonide and procaterol in a single inhaler. Budesonide is a corticosteroid that treats underlying airway inflammation in asthma. Procaterol is a direct acting sympathomimetic with predominantly Beta-adrenoceptor stimulant activity selective to Beta-2 receptors (a Beta-2 agonist). It is used as a bronchodilator in the management of reversible airways obstructive pulmonary disease. Budesonide and Procaterol therefore have complementary effects, treating two different components of asthma.
Detailed description
Test drug : SYN006 HFA MDI (Budesonide + Procaterol Hydrochloride) Strength: (Budesonide 180ug and Procaterol Hydrochloride 10ug/puff) Mode of administration: Orally inhaled administration, single dose (4 puffs) Reference drug 1 : Pulmicort pMDI (Budesonide) Strength: (Budesonide 200ug/puff) Mode of administration: Orally inhaled administration, single dose (4 puffs) Reference drug 2 : Meptin Air 10ug (Procaterol Hydrochloride) Strength: (Procaterol Hydrochloride 10ug/puff) Mode of administration: Orally inhaled administration, single dose (4 puffs) One dose for each drug (Test, Reference 1 and Reference 2)with an at least 6-day washout period.
Interventions
DRUGBudesonide
DRUGProcaterol
Sponsors
Intech Biopharm Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
* 1\. Provision of signed written informed consent before enrollment into the study, ability to communicate with the investigators, and to understand and comply with the requirements of the study. * 2\. Healthy adults, aged between 20 and 40 years old. * 3\. Subjects with Body Mass Index (BMI) of ≧18.5 and ≦25.0 (BMI will be calculated as weight in kilogram \[kg\]/height in meters2 \[m2\]). * 4\. Physically and mentally healthy subjects as confirmed by an interview, medical history, clinical examination, chest x-ray and electrocardiogram. * 5\. No significant deviation from normal biochemistry examination. * 6\. No significant deviation from normal hematology examination. * 7\. No significant deviation from normal urinalysis examination.
Exclusion criteria
* 1\. History of drug or alcohol abuse within the past year. * 2\. Medical history of severe drug allergy or sensitivity to analogous drug. * 3\. Evidence of acute or chronic diseases or having undergone surgery from 4 weeks prior to Period I dosing. * 4\. Evidence of any clinical significant renal, cardiovascular, hepatic, hematopoietic, neurological, pulmonary or gastrointestinal pathology. * 5\. Planned vaccination during the time course of the study. * 6\. Taking any clinical investigation drug from 2 months prior to Period I dosing. * 7\. Use of any medication, including herb medicine from 4 weeks before dosing. * 8\. Donation of 500 mL of blood in the past 3 months prior to dosing or donation of 250 mL of blood in the past 2 months prior to dosing. * 9\. A positive Hepatitis B surface antigen or positive Hepatitis C antibody result. * 10.A positive test for HIV antibody. * 11.In screening subjects will be given training to ensure that subjects are able to correctly use the investigational products. If the subjects, the use of the investigational products lack of proficiency will not be included in this study. * 12.Students of National Defense Medical Center. * 13.For female subjects, if they meet any of the following criteria: 1. Lactating women 2. Positive pregnancy test (urine) at screening, or prior to dosing 3. Do not use adequate contraception during the study 4. Women taking oral contraceptives
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area Under Curve (AUC) | predose, 0.083, 0.167, 0.333, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14 hours post-dose |
| Maximum plasma concentration (Cmax) | predose, 0.083, 0.167, 0.333, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14 hours post-dose |
| Time to reach Maximum plasma concentration (Tmax) | predose, 0.083, 0.167, 0.333, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14 hours post-dose |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mean residence time (MRT) | predose, 0.083, 0.167, 0.333, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14 hours post-dose | To evaluate the safety of the formulations used. The other PK-variables were assessed for description purposes. As safety parameters, adverse events and vital signs (blood pressure, heart rate and body temperature) were recorded. |
| Plasma elimination rate constant | predose, 0.083, 0.167, 0.333, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14 hours post-dose | To evaluate the safety of the formulations used. The other PK-variables were assessed for description purposes. As safety parameters, adverse events and vital signs (blood pressure, heart rate and body temperature) were recorded. |
Countries
Taiwan
Outcome results
None listed